SCHEMBL7089706

SCHEMBL7089706

O=[N+]([O-])c1c(Cl)ccc2nonc12

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.66
KMT2A Q03164 3/20 0.66
USP2 O75604 1/20 0.66
KEAP1 Q14145 1/20 0.66
NFE2L2 Q16236 1/20 0.66
ARNT P27540 12/20 0.63
EPAS1 Q99814 12/20 0.63
MAPT P10636 4/20 0.52
LMNA P02545 3/20 0.51
ALDH1A1 P00352 2/20 0.51
NPC1 O15118 1/20 0.51
TP53 P04637 1/20 0.51
HPGD P15428 1/20 0.51
XBP1 P17861 1/20 0.51
HTT P42858 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
TLR9 Q9NR96 1/20 0.51
POLB P06746 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7073313 0.81 KMT2A (0.68) MEN1KMT2AUSP2KEAP1NFE2L2
SCHEMBL15716688 0.79 KMT2A (1.00) MEN1KMT2AUSP2KEAP1NFE2L2
SCHEMBL3503925 0.79 KMT2A (1.00) MEN1KMT2AUSP2KEAP1NFE2L2
SCHEMBL16111786 0.79 KMT2A (0.66) MEN1KMT2AUSP2KEAP1NFE2L2
SCHEMBL4370342 0.79 MEN1 (0.66) MEN1KMT2AUSP2KEAP1NFE2L2
SCHEMBL28411867 0.79 KMT2A (0.71) MEN1KMT2AUSP2KEAP1NFE2L2
SCHEMBL15740027 0.78 ARNT (1.00) MEN1KMT2AARNTEPAS1MAPT
SCHEMBL15740036 0.77 ARNT (1.00) MEN1KMT2AARNTEPAS1MAPT
SCHEMBL31557738 0.77 ARNT (1.00) MEN1KMT2AARNTEPAS1MAPT
SCHEMBL18825636 0.76 KMT2A (0.53) MEN1KMT2AUSP2KEAP1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3405777-B1 OPTICAL SENSORS FOR DOWNHOLE TOOLS AND RELATED SYSTEMS AND METHODS BAKER HUGHES HOLDINGS LLC (US) 2023-03-01 EP claimed
EP-3405777-A1 OPTICAL SENSORS FOR DOWNHOLE TOOLS AND RELATED SYSTEMS AND METHODS Baker Hughes, a GE company, LLC (US) 2018-11-28 EP claimed
US-10025000-B2 Optical sensors for downhole tools and related systems and methods BAKER HUGHES INCORPORATED (US) 2018-07-17 US claimed
WO-2017127411-A1 OPTICAL SENSORS FOR DOWNHOLE TOOLS AND RELATED SYSTEMS AND METHODS BAKER HUGHES INCORPORATED (US) 2017-07-27 WO claimed
US-20170212272-A1 OPTICAL SENSORS FOR DOWNHOLE TOOLS AND RELATED SYSTEMS AND METHODS BAKER HUGHES INCORPORATED 2017-07-27 US claimed
US-RE49948-E1 Aryl ethers and uses thereof PELOTON THERAPEUTICS, INC. (US) 2024-04-30 US disclosed
EP-3405777-B1 OPTICAL SENSORS FOR DOWNHOLE TOOLS AND RELATED SYSTEMS AND METHODS BAKER HUGHES HOLDINGS LLC (US) 2023-03-01 EP disclosed
EP-3268362-B1 SUBSTITUTED PYRIDINES AND USES THEREOF PELOTON THERAPEUTICS INC (US) 2021-10-20 EP disclosed
CN-110372550-B Aryl ethers and their use 佩洛通治疗公司 2021-08-24 CN disclosed
US-10807948-B2 Aromatic compounds and uses thereof PELOTON THERAPEUTICS, INC. (US) 2020-10-20 US disclosed
US-10786480-B2 Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof PELOTON THERAPEUTICS, INC. (US) 2020-09-29 US disclosed
EP-3417851-B1 ARYL ETHERS AND USES THEREOF PELOTON THERAPEUTICS INC (US) 2020-07-22 EP disclosed
EP-3043784-A1 ARYL ETHERS AND USES THEREOF Peloton Therapeutics, Inc. (US) 2016-07-20 EP disclosed
WO-2016057242-A1 HIF-2α INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-04-14 WO disclosed
EP-2919770-A2 INHIBITION OF HIF-2 HETERODIMERIZATION WITH HIF1 (ARNT) The Board of Regents of The University of Texas System (US) 2015-09-23 EP disclosed
WO-2015035223-A1 ARYL ETHERS AND USES THEREOF PELOTON THERAPEUTICS, INC. (US) 2015-03-12 WO disclosed
WO-2014078479-A2 INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-05-22 WO disclosed
WO-2014078479-A2 INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT) THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-05-22 WO disclosed
US-20030044403-A1 Anti-infective therapy GENENTECH, INC. 2003-03-06 US disclosed
EP-0307390-A2 Chemical compound consisting of cis-3-hydroxyproline for therapeutic treatment, and process for its preparation MERCKLE GMBH (DE) 1989-03-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10786480-B2 Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof HIF1AN, HIF1A, EGLN2 MEN1 4089/4885KMT2A 186/4885USP2 696/4885
US-10807948-B2 Aromatic compounds and uses thereof VHL, HIF1AN, HIF1A MEN1 4167/4885KMT2A 510/4885USP2 766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.